Analyst action: Healthways, Pinnacle, Synovus
Posted on October 26, 2009 at 12:46 pm
After Healthways’ big gain following its Q3 report, Stifel Nicolaus analyst Tom Carroll has lowered his rating on the disease manager (Ticker: HWAY) to ‘hold’ from ‘buy.’ The valuation-based call is diametrically opposed to that of Art Henderson at Jefferies, who on Friday upgraded Healthways and raised his target to $20. So far, Carroll is winning: Healthways is down 7 percent today.
At Zacks Investment Research, shares of Pinnacle Financial are now on the ‘exclusive’ list of stocks investors should sell or avoid in the coming months. Pinnacle (Ticker: PNFP) last week reported a larger-than-expected loss.
And in related regional banking news, Wunderlich analyst Kevin Reynolds has some strong words on Synovus Financial Group, the parent of The Bank of Nashville. Reynolds has dropped Synovus to a ’sell’ and slapped a price target of $1.50 on the shares — half the price at the open today. The company last week posted a loss of more than $400 million and its stock (Ticker: SNV) has fallen more than 60 percent this year.
